1. |
Sabatini DM,Erdjument-Bromage H,Lui M,et al.RAFT1:a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.Cell,1994,78:35-43.
|
2. |
Brown EJ,Albers MW,Shin TB,et al.A mammalian protein targeted by G1-arresting rapamycin-receptor complex.Nature,1994,369:756-758.
|
3. |
Balsara BR,Pei J,Mitsuuchi Y,et al.Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.Carcinogenesis,2004,25:2053-2059.
|
4. |
Herberger B,Puhalla H,Lehnert M,et al,Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma.Clin Cancer Res,2007,13:4795-4799.
|
5. |
Gera JF,Mellinghoff IK,Shi Y,et al.AKT activity determines sensitivity to mammalian target of rapamycin(mTOR) inhibitors by regulating cyclin D1 and c-myc expression.J Biol Chem,2004,279:2737-2746.
|
6. |
Bjornsti MA,Houghton PJ.The TOR pathway:a target for cancer therapy.Nat Rev Cancer,2004,4:335-348.
|
7. |
Nave BT,Ouwens M,Withers DJ,et al.Mammalian target of rapamycin is a direct target for protein kinase B:identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation.Biochem J,1999,344:427-431.
|
8. |
Sekulic A,Hudson CC,Homme JL,et al.A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.Cancer Res,2000,60:3504-3513.
|
9. |
Scott PH,Lawrence JC Jr.Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3–L1 adipocytes.J Biol Chem,1998,273:34496-34501.
|
10. |
Reynolds TH 4th,Bodine SC,Lawrence JC Jr.Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load.J Biol Chem,2002,277:17657-17662.
|
11. |
Sahin F,Kannangai R,Adegbola O,et al.mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms.Clin Cancer Res,2004,10:8421-8425.
|
12. |
Zhou X,Tan M,Stone Hawthorne V,et al.Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers.Clin Cancer Res,2004,10:6779-6788.
|
13. |
Faried LS,Faried A,Kanuma T,et al.Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy.Oncol Rep,2006,16:57-63.
|
14. |
Kremer CL,Klein RR,Mendelson J,et al.Expression of mTOR Signaling PathwayMarkers in Prostate Cancer Progression.Prostate,2006,66:1203-1212.
|
15. |
Sieghart W,Fuereder T,Schmid K,et al.Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.Transplantation,2007,83:425-432.
|
16. |
Atkins MB,Hidalgo M,Stadler WM,et al.Randomized phase II study of multiple dose levels of CCI-779,a novel mammalian target of rapamycin kinase inhibitor,in patients with advanced refractory renal cell carcinoma.J Clin Oncol,2004,22:909-918.
|
17. |
Witzig TE,Geyer SM,Ghobrial I,et al.Phase II trial of single-agent temsirolimus(CCI-779) for relapsed mantle cell lymphoma.J Clin Oncol,2005,23:5347-5356.
|
18. |
Galanis E,Buckner JC,Maurer MJ,et al.Phase II trial of temsirolimus(CCI-779) in recurrent glioblastoma multiforme:a North Central Cancer Treatment Group Study.J Clin On col,2005,23:5294-5304.
|
19. |
Chan S,Scheulen ME,Johnston S,et al.Phase II study of temsirolimus(CCI-779),a novel inhibitor of mTOR,in heavily pretreated patients with locally advanced or metastatic breast cancer.J Clin Oncol,2005,23:5314-5322.
|